1249. Deputy Mark Wall asked the Minister for Health to clarify whether AEDs are covered under the drugs payment scheme; and if she will make a statement on the matter. [33443/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
441. Deputy Michael Fitzmaurice asked the Minister for Health when brensocatib, although approved will be made available in Ireland; and if she will make a statement on the matter. [31571/26]
445. Deputy Michael Cahill asked the Minister for Health the percentage of the HSE medicines budget that is currently spent on 'non-oncology medicines for rare diseases; and if she will make a statement on the matter. [31631/26]
453. Deputy Marie Sherlock asked the Minister for Health if she has requested the NCPP to consider a full review of relugolix with estradiol and norethisterone acetate. [31687/26]
454. Deputy Marie Sherlock asked the Minister for Health the submitted price of ryeqo (relugolix with estradiol and norethisterone acetate) at the time of the rapid review by the NCPP in 2022. [31688/26]
455. Deputy Marie Sherlock asked the Minister for Health to list the grounds upon which the NCPP rejected a full HTA examination of Ryeqo. [31689/26]
272. Deputy Jennifer Whitmore asked the Minister for Health if she will consider approving access to xolair for a person (details supplied); and if she will make a statement on the matter. [31098/26]
274. Deputy Thomas Gould asked the Minister for Health whether she will intervene to ensure that the HSE urgently prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for Frederich's ataxia which currently can be classed as having an 'unmet need' as outlined in the National Rare Disease Strategy 2025 - 2030. [31101/26]
275. Deputy Thomas Gould asked the Minister for Health her views on whether the current delay in the reimbursement of skyclarys aligns with the equitable access promised in the newly launched National Rare Disease Strategy 2025-2030. [31102/26]
999. Deputy Paul Donnelly asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the skyclarys reimbursement negotiations (details supplied); and her views on whether the current delay aligns with the equitable access promised in the newly launched National Rare Disease Strategy 2025-2030. [29564/26]
1000. Deputy Louis O'Hara asked the Minister for Health the measures being taken to improve the timeliness of access to orphan drugs in Ireland, particularly in cases such as Friedreich's ataxia, where a treatment has been approved by the EMA but is not yet reimbursed by the HSE; and if she will make a statement on the matter. [29565/26]
1184. Deputy Martin Daly asked the Minister for Health if she will intervene to ensure that the Health Service Executive urgently prioritises the conclusion of reimbursement negotiations for skyclarys for the treatment of Friedreich’s ataxia, given that it is currently the only available treatment for this progressive and life-limiting rare disease and that Friedreich’s ataxia may be considered as having an “unmet ne…
1185. Deputy Martin Daly asked the Minister for Health her views on whether the ongoing delay in concluding reimbursement negotiations for skyclarys for patients with Friedreich’s ataxia is consistent with the commitment to “equitable access” set out in the recently launched National Rare Disease Strategy 2025–2030; and if she will make a statement on the matter. [30202/26]
1274. Deputy Roderic O'Gorman asked the Minister for Health the reason imvaggis is not covered by the free HRT scheme; if consideration can be given to its inclusion in the scheme; and if she will make a statement on the matter. [30897/26]
1276. Deputy Pádraig O'Sullivan asked the Minister for Health whether her Department has identified which of the medicines currently in shortage across the European Union may pose a risk of shortage in Ireland; the measures in place to ensure continuity of supply and minimise patient impact; and if she will make a statement on the matter. [30904/26]
1278. Deputy Cormac Devlin asked the Minister for Health if she will provide an update on the NCPE appraisal of ritlecitinib (litfulo) for severe alopecia areata, including current stage, any ongoing HSE pricing and reimbursement engagement with the applicant, expected timelines for a decision, and proposed prescribing setting if approved (details supplied); and if she will make a statement on the matter. [30914/26]
1279. Deputy Cormac Devlin asked the Minister for Health if an application has been received by the HSE for pricing and reimbursement of baricitinib for the alopecia areata indication; if not, whether the HSE or her Department has engaged with the marketing authorisation holder regarding a submission (details supplied); and if she will make a statement on the matter. [30915/26]
1280. Deputy Cormac Devlin asked the Minister for Health whether her Department, the HSE or the HPRA has engaged with the manufacturer of deuruxolitinib (leqselvi) regarding plans for EU submission and availability in Ireland; whether any named-patient or compassionate access requests have been received (details supplied); and if she will make a statement on the matter. [30916/26]
1281. Deputy Cormac Devlin asked the Minister for Health if she will outline whether JAK inhibitor treatments for severe alopecia areata, where reimbursed, will be provided via the High Tech Arrangement; the intended initiation and monitoring setting; the proposed stop rules; the estimated annual budget impact and eligible patient numbers (details supplied); and if she will make a statement on the matter. [30917/26]
1282. Deputy Cormac Devlin asked the Minister for Health the number of patients treated for alopecia areata with JAK inhibitors in public hospitals in each of the past three years, by CHO and by medicine, including any named-patient access, and associated monitoring protocols; and if she will make a statement on the matter. [30918/26]
554. Deputy Gillian Toole asked the Minister for Health the reason drug companies are indemnified if vaccines are presented to the public as being safe and effective. [29477/26]
558. Deputy Gillian Toole asked the Minister for Health the reason drug companies indemnified are if vaccines are presented to the public as being safe and effective. [29492/26]
565. Deputy Eoghan Kenny asked the Minister for Health if her Department has considered the inclusion of skyclarys (omaveloxolone) which is a treatment for Friedreich's ataxia in a reimbursement scheme given the cost of the drug and the fact that other European countries provide this scheme to patients; and if she will make a statement on the matter. [29555/26]
221. Deputy Niamh Smyth asked the Minister for Health if she will review matters raised in correspondence (details supplied); if she will provide an update on the HSE's decision regarding the reimbursement of skyclarys for the treatment of Friedreich's ataxia; if she will note that 619 days have elapsed since the application for reimbursement was submitted by the pharmaceutical company; the timeline for a decision; a…
239. Deputy Ken O'Flynn asked the Minister for Health whether an application has been received for the reimbursement of the drug skyclarys for the treatment of Friedreich’s ataxia; if so, the current status of that application; the date on which it was submitted to the National Centre for Pharmacoeconomics; and the expected timeline for a final reimbursement decision. [29078/26]